Novartis, Incyte join repurposing wave to give Jakavi drug a trial run in Covid-19
[ZURICH] Novartis and Incyte plan to test their drug Jakavi in patients with coronavirus-caused Covid-19, joining other firms including Roche and Sanofi hoping to repurpose older medicines to help critically ill patients.
Jakavi is used in adults with bone marrow cancer, or myelofibrosis, among other conditions. Novartis and Incyte want to see if it helps Covid-19 patients suffering from an immune system overreaction, also called a cytokine storm.
They are still putting together trial details, Novartis said.
The lack of an approved treatment for Covid-19 has prompted companies and doctors to rush back to their medicine cabinets in a desperate hunt for something to help keep thousands more patients from dying than standard care alone.
Roche has announced trials of its arthritis drug Actemra while Sanofi and Regeneron are testing their arthritis medicine Kevzara against severe immune reactions that endanger coronavirus patients' lives. Some data from China suggest medicines against cytokine storms help save patients.
"The potential that Jakavi could lead to faster recovery times for Covid-19 patients with fewer requiring intensive care and mechanical ventilation is encouraging and absolutely merits further investigation," said John Tsai, Novartis's top drug developer.
GET BT IN YOUR INBOX DAILY
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
Novartis plans a compassionate use programme for Covid-19 access, while making sure there is enough Jakavi to go around for approved indications, it said. Jakavi had US$1.1 billion in sales for Novartis last year, and US$1.7 billion for Incyte, which sells it in the United States under the name Jakafi.
Novartis previously joined other companies including Mylan, Teva and Bayer in donating older malaria drugs that are also undergoing trials and being used in emergency settings.
Reuters
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue